- Home
- ABSI
ABSI
Absci Corporation
as 05-30-2025 4:00pm EST
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 353.8M | IPO Year: | 2021 |
| Target Price: | $8.40 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $6.33 | Next Earning Date: | 05-13-2025 |
| Revenue: | $4,815,000 | Revenue Growth: | -9.95% |
| Revenue Growth (this year): | 145.79% | Revenue Growth (next year): | 99.29% |
Latest Absci Corporation News
ABSI Breaking Stock News: Dive into ABSI Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Absci to Participate in Upcoming Investor Conferences
Simply Wall St.
16 days ago
Absci First Quarter 2025 Earnings: Beats Expectations
Thomson Reuters StreetEvents
17 days ago
Q1 2025 Absci Corp Earnings Call
GuruFocus.com
18 days ago
Absci Corp (ABSI) Q1 2025 Earnings Call Highlights: Transition to Clinical Stage and Strong ...
Zacks
18 days ago
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
18 days ago
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
GlobeNewswire
18 days ago
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
GuruFocus.com
19 days ago
What To Expect From Absci Corp (ABSI) Q1 2025 Earnings
Compare ABSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABSI Absci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.